Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

11.10USD
9 Dec 2016
Change (% chg)

$0.30 (+2.78%)
Prev Close
$10.80
Open
$10.90
Day's High
$11.30
Day's Low
$10.85
Volume
95,594
Avg. Vol
110,477
52-wk High
$18.06
52-wk Low
$7.03

EPZM.OQ

Chart for EPZM.OQ

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes... (more)

Overall

Beta: 2.26
Market Cap(Mil.): $626.52
Shares Outstanding(Mil.): 58.01
Dividend: --
Yield (%): --

Financials

  EPZM.OQ Industry Sector
P/E (TTM): -- 40.79 30.35
EPS (TTM): -1.85 -- --
ROI: -40.31 -0.56 15.27
ROE: -46.02 -1.20 16.60

BRIEF-Epizyme announces fast track designation for Tazemetostat in DLBCL

* Epizyme announces fast track designation for tazemetostat in DLBCL and provides solid tumor program update

Nov 28 2016

BRIEF-Epizyme Q3 loss per share $0.42

* Says plans to report efficacy, safety and biomarker data from both phase 2 studies on tazemetostat in first half of 2017

Nov 03 2016

BRIEF-Epizyme appoints Pamela Strode as vice president

* Epizyme appoints Pamela Strode as vice president, regulatory affairs and quality assurance Source text for Eikon: Further company coverage:

Sep 29 2016

BRIEF-Epizyme earns $6 million from Glaxosmithkline for initiation of clinical development

* Earns $6 million milestone payment from Glaxosmithkline for initiation of clinical development with first in-class PRMT5 inhibitor

Sep 15 2016

BRIEF-Epizyme's Tazemetostat study surpassed pre-specified futility hurdle - committee

* Independent data monitoring committee confirmed that study cohort related to tazemetostat has surpassed its pre-specified futility hurdle

Sep 07 2016

BRIEF-Epizyme reported Q2 EPS ($0.49)

* Epizyme announces second quarter 2016 financial results and progress against corporate objectives

Aug 08 2016

BRIEF-Epizyme initiates collaboration on combination trial of tazemetostat and tecentriq for treatment of Non-Hodgkin Lymphoma

* Epizyme initiates collaboration on combination trial of tazemetostat and tecentriq(tm)(atezolizumab) for treatment of Non-Hodgkin Lymphoma

Jun 22 2016

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,881 +606.00
Novartis AG (NOVN.S) CHF70.75 +2.25
GlaxoSmithKline plc (GSK.L) 1,478.00p +18.00
Celgene Corporation (CELG.OQ) $113.47 +0.41

Earnings vs. Estimates